Proactive Investors
02 Sept 2026, 12:54 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
2 claims · each scored for market impact
Immunic Inc expects to release topline results from its Phase 3 ENSURE trials for vidofludimus calcium by the end of 2026. — Phase 3 results are the primary value-driver for biotech companies and typically trigger significant price volatility upon release.
+0.80Immunic will host a virtual R&D day on September 9 to discuss its investigational relapsing multiple sclerosis therapy. — R&D days provide insight and sentiment but rarely move prices as significantly as actual clinical data.
+0.20Which stocks this story touches
The company is hosting an R&D day and progressing toward Phase 3 trial results for its MS therapy.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
1d ago
